{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:04:14Z","timestamp":1789038254694,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011912","name":"Washington University School of Medicine in Saint Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK020579"],"award-info":[{"award-number":["P30DK020579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002345"],"award-info":[{"award-number":["UL1TR002345"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008116","name":"Diabetes Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA091842"],"award-info":[{"award-number":["P30CA091842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA171063"],"award-info":[{"award-number":["P50CA171063"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA171963"],"award-info":[{"award-number":["P50CA171963"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA210084"],"award-info":[{"award-number":["R35CA210084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007930","name":"Institute of Clinical and Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014571","name":"Alvin J. Siteman Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Immunology & Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bict.2025.100012","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:41:04Z","timestamp":1759797664000},"page":"100012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9090-8505","authenticated-orcid":false,"given":"Aditya R.","family":"Yelamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezhilarasi","family":"Chendamarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Ritchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-0564","authenticated-orcid":false,"given":"Michael P.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7733-5509","authenticated-orcid":false,"given":"Stephen P.","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bict.2025.100012_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bict.2025.100012_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bict.2025.100012_bib3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bict.2025.100012_bib4","article-title":"Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: a review","volume":"10","author":"Bhalla","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-022-01284-6","article-title":"Worked to the bone: antibody-based conditioning as the future of transplant biology","volume":"15","author":"Griffin","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.bict.2025.100012_bib6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ymthe.2018.03.003","article-title":"Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment","volume":"26","author":"Arai","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.bict.2025.100012_bib8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib9","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.bict.2025.100012_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.05.018","article-title":"Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance","volume":"25","author":"George","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41467-018-08202-w","article-title":"Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.bict.2025.100012_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145501","article-title":"Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation","volume":"131","author":"Persaud","year":"2021","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.bict.2025.100012_bib13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bict.2025.100012_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized phase III SIERRA trial of 131I-Apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bict.2025.100012_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.bict.2025.100012_bib17","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.bict.2025.100012_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/toxins15030181","article-title":"Streptavidin-saporin: converting biotinylated materials into targeted toxins","volume":"15","author":"Ancheta","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.bict.2025.100012_bib20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2022-157726","article-title":"Fully myeloablative antibody-drug conjugates condition for hematopoietic stem cell transplantation and provide durable antileukemia benefit [abstract]","volume":"140","author":"Persaud","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bict.2025.100012_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bict.2025.100012_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bict.2025.100012_bib23","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/psp4.12833","article-title":"Development of and insights from systems pharmacology models of antibody-drug conjugates","volume":"11","author":"Lam","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.bict.2025.100012_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/d41587-019-00017-4","article-title":"Click chemistry targets antibody-drug conjugates for the clinic","volume":"37","author":"Peplow","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"17","key":"10.1016\/j.bict.2025.100012_bib25","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1182\/bloodadvances.2023012457","article-title":"Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation","volume":"8","author":"Persaud","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bict.2025.100012_bib26","first-page":"1008","article-title":"Endogenous and combination retinoids are active in myelomonocytic leukemias","volume":"106","author":"Di Martino","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bict.2025.100012_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061332","article-title":"Whole-body pharmacokinetics and physiologically based pharmacokinetic model for monomethyl auristatin E (MMAE)","volume":"10","author":"Chang","year":"2021","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.bict.2025.100012_bib28","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jacsau.2c00448","article-title":"40 years of duocarmycins: a graphical structure\/function review of their chemical evolution, from SAR to prodrugs and ADCs","volume":"2","author":"Felber","year":"2022","journal-title":"JACS Au"},{"issue":"24","key":"10.1016\/j.bict.2025.100012_bib29","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1016\/j.bmc.2012.10.033","article-title":"The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs","volume":"20","author":"Mazzini","year":"2012","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"issue":"7763","key":"10.1016\/j.bict.2025.100012_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-019-1244-x","article-title":"Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation","volume":"571","author":"Wilkinson","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bict.2025.100012_bib32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41596-019-0263-2","article-title":"Long-term ex vivo expansion of mouse hematopoietic stem cells","volume":"15","author":"Wilkinson","year":"2020","journal-title":"Nat Protoc"},{"issue":"suppl 15","key":"10.1016\/j.bict.2025.100012_bib33","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1200\/JCO.2019.37.15_suppl.7048","article-title":"Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (131I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial","volume":"37","author":"Tomlinson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bict.2025.100012_bib34","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-05-3443","article-title":"A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.bict.2025.100012_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209034","article-title":"Improved multilineage human hematopoietic reconstitution and function in NSGS mice","volume":"13","author":"Wunderlich","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bict.2025.100012_bib36","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bict.2025.100012_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molimm.2020.08.015","article-title":"Cross-reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding","volume":"127","author":"Temming","year":"2020","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.bict.2025.100012_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bict.2025.100012_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.835677","article-title":"The use of antibody-antibiotic conjugates to fight bacterial infections","volume":"13","author":"Cavaco","year":"2022","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.bict.2025.100012_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040838","article-title":"Antibody-oligonucleotide conjugates: a twist to antibody-drug conjugates","volume":"10","author":"Dugal-Tessier","year":"2021","journal-title":"J Clin Med"},{"issue":"21","key":"10.1016\/j.bict.2025.100012_bib42","doi-asserted-by":"crossref","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","article-title":"Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy","volume":"64","author":"He","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bict.2025.100012_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/gzac011","article-title":"Antibody-mediated delivery of CRISPR-Cas9 ribonucleoproteins in human cells","volume":"35","author":"Ubiparipovic","year":"2022","journal-title":"Protein Eng Des Sel"},{"issue":"6","key":"10.1016\/j.bict.2025.100012_bib44","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem Biol"},{"issue":"6","key":"10.1016\/j.bict.2025.100012_bib45","first-page":"546","article-title":"Immunotoxin therapy of hematological malignancies","volume":"80","author":"Pasqualucci","year":"1995","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bict.2025.100012_bib46","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/toxins5101698","article-title":"Saporin-S6: a useful tool in cancer therapy","volume":"5","author":"Polito","year":"2013","journal-title":"Toxins"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib47","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1038\/s41598-020-65860-x","article-title":"Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer antibody-drug conjugates (ADCs)","volume":"10","author":"Hoffmann","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bict.2025.100012_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib49","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/s41467-022-31601-z","article-title":"Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy","volume":"13","author":"Hingorani","year":"2022","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.bict.2025.100012_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.bict.2025.100012_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.bict.2025.100012_bib52","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1158\/1535-7163.MCT-18-0329","article-title":"Unraveling the interaction between carboxylesterase 1c and the antibody-drug conjugate SYD985: improved translational PK\/PD by using Ces1c knockout mice","volume":"17","author":"Ubink","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.bict.2025.100012_bib53","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1038\/s41467-018-04982-3","article-title":"Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice","volume":"9","author":"Anami","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.bict.2025.100012_bib54","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"23","key":"10.1016\/j.bict.2025.100012_bib55","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1021\/acs.jmedchem.7b00736","article-title":"Pyrrolobenzodiazepine dimer antibody-drug conjugates: synthesis and evaluation of noncleavable drug-linkers","volume":"60","author":"Gregson","year":"2017","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bict.2025.100012_bib56","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.ymthe.2024.03.032","article-title":"Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant","volume":"32","author":"Yeung","year":"2024","journal-title":"Mol Ther"}],"container-title":["Blood Immunology & Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597625000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597625000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:10:11Z","timestamp":1780909811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050597625000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S3050597625000120"],"URL":"https:\/\/doi.org\/10.1016\/j.bict.2025.100012","relation":{},"ISSN":["3050-5976"],"issn-type":[{"value":"3050-5976","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Streptavidin-drug conjugates streamline optimization of antibody-based hematopoietic stem cell transplant conditioning","name":"articletitle","label":"Article Title"},{"value":"Blood Immunology & Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bict.2025.100012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100012"}}